Australian pharmaceutical company Avexa reported that late-stage trials of its HIV med apricitabine (ATC), a nucleoside reverse transcriptase inhibitor, proved the drug is highly effective in treating HIV-positive people who have developed resistance to other meds. They hope to get ATC on shelves by 2010.